An experimental drug insert designed to reduce how often people with wet age-related macular degeneration need eye injections failed to meet its main goal in the first of two pivotal trials, its manufacturer announced.
EyePoint reported that DURAVYU, a vorolanib intravitreal insert, did not achieve the primary endpoint of the phase 3 LUGANO trial. That endpoint was changed from baseline in best corrected visual acuity, averaged across weeks 52 and 56, measured against on-label aflibercept, the current standard of care.
